• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    5/20/24 8:06:50 AM ET
    $AIH
    $AKAN
    $CPHI
    $GTBP
    Medical Specialities
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $AIH alert in real time by email

    Gainers

    • GT Biopharma (NASDAQ:GTBP) stock rose 153.2% to $7.9 during Monday's pre-market session. The company's market cap stands at $10.9 million. As per the press release, Q1 earnings came out 3 days ago.
    • China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares rose 42.9% to $0.47. As per the news, the Q1 earnings report came out 3 days ago.
    • Kintara Therapeutics (NASDAQ:KTRA) shares rose 28.95% to $0.18. The market value of their outstanding shares is at $7.1 million. The company's, Q3 earnings came out 4 days ago.
    • PTC Therapeutics (NASDAQ:PTCT) stock rose 26.9% to $42.0. The market value of their outstanding shares is at $3.2 billion.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 25.21% to $1.44. The company's market cap stands at $1.3 million.
    • Cue Health (NASDAQ:HLTH) stock rose 24.48% to $0.12. The company's market cap stands at $19.0 million.

    Losers

    • Virios Therapeutics (NASDAQ:VIRI) shares fell 44.1% to $0.2 during Monday's pre-market session. The company's market cap stands at $3.7 million.
    • Jaguar Health (NASDAQ:JAGX) shares fell 39.46% to $0.16. The market value of their outstanding shares is at $45.9 million. The company's, Q1 earnings came out 4 days ago.
    • Aesthetic Medical Intl (NASDAQ:AIH) shares fell 27.68% to $0.36. The company's market cap stands at $17.2 million.
    • Akanda (NASDAQ:AKAN) shares declined by 23.01% to $0.13. The company's market cap stands at $4.2 million.
    • Syra Health (NASDAQ:SYRA) shares decreased by 11.95% to $1.4. The market value of their outstanding shares is at $8.9 million.
    • Tenon Medical (NASDAQ:TNON) shares decreased by 9.58% to $0.77. The company's market cap stands at $2.8 million. As per the press release, Q1 earnings came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIH
    $AKAN
    $CPHI
    $GTBP

    CompanyDatePrice TargetRatingAnalyst
    PTC Therapeutics Inc.
    $PTCT
    1/28/2026$119.00Overweight
    Barclays
    PTC Therapeutics Inc.
    $PTCT
    12/1/2025$91.00Outperform → Sector Perform
    RBC Capital Mkts
    PTC Therapeutics Inc.
    $PTCT
    10/20/2025$73.00Overweight
    Wells Fargo
    PTC Therapeutics Inc.
    $PTCT
    6/17/2025$80.00Buy
    Truist
    PTC Therapeutics Inc.
    $PTCT
    5/9/2025$68.00Neutral → Buy
    BofA Securities
    PTC Therapeutics Inc.
    $PTCT
    5/7/2025$40.00Sell → Neutral
    Citigroup
    PTC Therapeutics Inc.
    $PTCT
    3/11/2025$41.00 → $55.00Underperform → Neutral
    BofA Securities
    PTC Therapeutics Inc.
    $PTCT
    3/7/2025$55.00Sector Perform
    Scotiabank
    More analyst ratings

    $AIH
    $AKAN
    $CPHI
    $GTBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory sold $252,823 worth of shares (3,989 units at $63.38) (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    3/9/26 5:20:05 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CHIEF MEDICAL OFFICER Golden Lee Scott sold $633,800 worth of shares (10,000 units at $63.38), decreasing direct ownership by 11% to 79,944 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    3/9/26 5:20:07 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Okey Stephanie sold $401,386 worth of shares (6,333 units at $63.38), decreasing direct ownership by 44% to 8,000 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    3/9/26 5:20:10 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AKAN
    $CPHI
    $GTBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Syra Health To Announce Fourth Quarter and Full Year 2025 Financial Results

    CARMEL, Ind., March 5, 2026 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA), ("Syra Health" or the "Company"), an integrated healthcare solutions company powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today that it will report financial results for its fourth quarter and fiscal year ended December 31, 2025, on Thursday, March 12, 2026. The results will be shared in a press release before the market opens.About Syra HealthSyra Health is an integrated healthcare solutions company serving government and commercial healthca

    3/5/26 7:55:00 AM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    GT Biopharma Reports Full Year 2025 Financial Results

    Phase 1 trial evaluating GTB-3650 TriKE® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 remains on track to initiate mid-2026 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, March 02, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural ki

    3/2/26 7:00:00 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    First Towers & Fiber Corp. Owns the Largest Dark Fiber Network in Central Mexico

    Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, announced today plans to further expand the leasing of its approximately 700-kilometre dark fiber optic network located in Central Mexico. The network represents the largest dark fiber infrastructure in the region, serving several of Mexico's most active industrial corridors and fastest-growing state economies.The network was constructed following the execution of a 20-year long-term dark fiber lease agreement with Telefónica, the Spanish multinationa

    2/27/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AIH
    $AKAN
    $CPHI
    $GTBP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AIH
    $AKAN
    $CPHI
    $GTBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on PTC Therapeutics with a new price target

    Barclays resumed coverage of PTC Therapeutics with a rating of Overweight and set a new price target of $119.00

    1/28/26 7:18:18 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded PTC Therapeutics from Outperform to Sector Perform and set a new price target of $91.00

    12/1/25 8:18:44 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on PTC Therapeutics with a new price target

    Wells Fargo initiated coverage of PTC Therapeutics with a rating of Overweight and set a new price target of $73.00

    10/20/25 8:02:41 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AKAN
    $CPHI
    $GTBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    CEO and President Foster Steven M bought 19,455 shares, increasing direct ownership by 568% to 22,878 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    11/18/25 8:42:50 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Chief Innovation Officer Geist Wyatt D. bought 19,455 shares, increasing direct ownership by 14% to 157,569 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    11/18/25 8:01:43 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    $AIH
    $AKAN
    $CPHI
    $GTBP
    SEC Filings

    View All

    Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    3/9/26 9:05:16 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Jaguar Health Inc.

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    3/6/26 4:15:47 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 10-Q/A filed by GT Biopharma Inc.

    10-Q/A - GT Biopharma, Inc. (0000109657) (Filer)

    3/6/26 4:01:05 PM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AKAN
    $CPHI
    $GTBP
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    – Full-year 2025 product and royalty revenue of $831M, exceeding guidance –– Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively –– Cash of $1.95B as of December 31, 2025 –WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.  "We delivered another strong quarter and finish to 2025, building on the successful global launch of Sephience," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "With our robust commercial engine, innovative R&D programs,

    2/19/26 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

    WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's business and outlook on Thursday, Feb. 19, 2026, at 4:30 p.m. ET. To access the call by phone, please click here to register and you will be provided with dial-in details. The webcast conference call can be accessed on the Investors section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call w

    2/5/26 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    – Initiated US and EU launch of Sephience™ (sepiapterin) –  – Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 – – Robust Q3 performance with total revenue of $211M – – Full-year 2025 revenue guidance narrowed to $750 - $800M – WARREN, N.J., Nov. 4, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2025.  "We achieved an outstanding quarter, highlighted by the strong start to the global Sephience launch," said Matthew B. Klein, M.D., Chief Executive Officer. "The broad initial uptake supports the potential of Sephience to b

    11/4/25 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AKAN
    $CPHI
    $GTBP
    Leadership Updates

    Live Leadership Updates

    View All

    Syra Health Appoints Healthcare Executive and Former U.S. Marine Gregory R. Alexander as Chief Executive Officer to Drive Growth

    Proven C-Suite Leader with Track Record of Scaling Healthcare Organizations Joins Syra Health to Accelerate Market Expansion and Industry Impact CARMEL, Ind., Dec. 18, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare solutions company dedicated to powering better health outcomes through prevention-focused, accessible, and affordable solutions, announced today the appointment of Gregory R. Alexander as Chief Executive Officer, effective January 5, 2026. Alexander's career has been defined by consistently driving growth and excee

    12/18/25 8:55:00 AM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AKAN
    $CPHI
    $GTBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/14/24 5:22:11 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PTC Therapeutics Inc.

    SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    11/8/24 10:52:39 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

    SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

    10/25/24 12:19:29 PM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care